What is Versavo?

Versavo is a biosimilar bevacizumab and is indicated for the treatment of multiple cancers. It is used in combination with other chemotherapy drugs to treat cervical, colorectal, glioblastoma and non-squamous non-small cell lung cancer.

Storage Conditions

2-8 degrees Celsius (refrigerate),Do not freeze.

Presentation

Vial containing concentrate for solution for infusion.

Route of Administration

Intravenous (IV) (upon prescription only and administered by a healthcare provider.)

Indications

Metastatic Colorectal Cancer (mCRC):

mCRC is a stage of colorectal cancer where it spreads beyond the colon or rectum to other parts of the body, often requiring aggressive treatment for better survival.

How Bevacizumab works?

Mechanism of Action

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

We Meet Global Standards

CDSCO
ISO 9001
INVIMA
SAHPRA

Our News, Stories, and Insights

Comparison of the Efficacy of Innovator
  • Publication
  • 06-08-2019

Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis

  • Publication
  • 30-09-2017

Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study

  • Article
  • 30-09-2023

Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?

  • Article
  • 16-07-2024

Mitigating target interference challenges in bridging immunogenicity assay to detect anti-t ocilizumab antibodies